Finally, because pancreatic cancer patients suffer from severe immunosuppression and dysfunction of T-cell populations,61 whether targeting GOT2 is sufficient to reverse the immune suppression in this case remains to be investigated. This evidence concerns the gene GOT2 and pancreatic neoplasm.